Alivus Life Sciences (NSE:ALIVUS) ROCE %: 24.99% (As of Mar. 2026)


NSE:ALIVUS Alivus Life Sciences Ltd NSE:ALIVUS
83 GF Score
Price ₹1,108.30
GF Value ₹1,012.74
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Alivus Life Sciences ROCE %?

Alivus Life Sciences NSE:ALIVUS -0.70% 83 ROCE % is 24.99% as of Mar. 2026. GuruFocus rates NSE:ALIVUS with a GF Score™ of 83/100 and a GF Value™ of ₹1,012.74 (Fairly Valued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alivus Life Sciences's annualized ROCE % for the quarter that ended in Mar. 2026 was 24.99%.

Alivus Life Sciences  (NSE:ALIVUS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alivus Life Sciences ROCE % Related Terms

Alivus Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Alivus Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alivus Life Sciences ROCE % Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial 41.42 29.31 27.41 24.53 23.59

Alivus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.19 22.33 22.29 25.39 24.99
NSE:ALIVUS
83GF Score
Alivus Life Sciences Ltd NSE:ALIVUS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alivus Life Sciences ROCE % Calculation

Alivus Life Sciences's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=7566.81/( ( (34114.53 - 4701.59) + (39828.97 - 5080.35) )/ 2 )
=7566.81/( (29412.94+34748.62)/ 2 )
=7566.81/32080.78
=23.59 %

Alivus Life Sciences's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=8684.32/( ( (0 - 0) + (39828.97 - 5080.35) )/ 1 )
=8684.32/( ( 0 + 34748.62 )/ 1 )
=8684.32/34748.62
=24.99 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 24.99% mean?
Alivus Life Sciences (NSE:ALIVUS) has a ROCE % of 24.99% as of Mar. 2026.
Is Alivus Life Sciences' ROCE % too high?
Alivus Life Sciences' current ROCE % is 24.99%. The Drug Manufacturers industry median ROCE % is 7.00. Alivus Life Sciences' value of 24.99% is 257.3% above this industry median. Overall, Alivus Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' ROCE % compare to ZTS?
Alivus Life Sciences' ROCE % of 24.99% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Alivus Life Sciences' value of 24.99% is 257.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current ROCE % of 24.99% is 257.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current ROCE % is 24.99%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,012.74, compared to a current price of ₹1,108.30 — trading 9.4% above its estimated fair value. The current ROCE % is 24.99% and 257.3% above the Drug Manufacturers industry median of 7.00. Alivus Life Sciences' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current ROCE % is 24.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?

Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued. The current stock price of ₹1,108.30 is trading 9.4% above its estimated GF Value™ of ₹1,012.74. GuruFocus considers Alivus Life Sciences to be Fairly Valued.

Key valuation signals for NSE:ALIVUS:

  • ROCE %: 24.99%
  • GF Value™: ₹1,012.74 vs. price of ₹1,108.30 (9.4% above fair value)
  • GF Score™: 83/100 with 4 warning signs
  • Industry Position: 257.3% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alivus Life Sciences Business Description

Other Exchanges 543322:India
Address 470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
83GF Score

Get the complete analysis for NSE:ALIVUS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,108.30
Price
₹1,012.74
GF Value